The global large and small-scale bioprocessing market was valued at USD 80.5 billion in 2024 and is projected to reach USD 228.7 billion by 2033, expanding at a CAGR of 11.86% from 2025 to 2033. This robust growth is primarily driven by rising global demand for biologics, including monoclonal antibodies, vaccines, and cell and gene therapies. Biopharmaceutical manufacturers continue to increase investments in flexible production platforms such as single-use systems and modular bioprocessing units, which help shorten development timelines and optimize manufacturing costs.

Key Market Trends & Insights

• North America dominated the global large and small-scale bioprocessing market with a 34.84% share in 2024.
• The U.S. led within North America due to its advanced biopharmaceutical manufacturing capacity.
• By workflow, downstream processing accounted for the largest share at 46.85% in 2024.
• By product, bioreactors/fermenters represented the leading segment with 29.10% market share in 2024.
• By scale, the industrial scale (over 50,000 liters) segment held the highest share in 2024.

Order a free sample PDF of the Large And Small-scale Bioprocessing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 80.5 Billion
• 2033 Projected Market Size: USD 228.7 Billion
• CAGR (2025-2033): 11.86%
• North America: Largest regional market in 2024
• Asia Pacific: Fastest-growing regional market

Key Large and Small-scale Bioprocessing Company Insights

The global large and small-scale bioprocessing landscape is shaped by a broad mix of established global leaders and specialized emerging companies. Major industry players such as Merck KGaA, Thermo Fisher Scientific, GE Healthcare, Sartorius AG, and Lonza maintain strong market positions through expansive product portfolios, manufacturing scale, and sustained investment in automation and advanced bioprocessing technologies.

Companies across Asia and Europe, including Samsung BioLogics, Binex Co., Ltd., Rentschler Biopharma, and Inno Biologics, are rapidly expanding their global presence through strategic alliances and regional cost advantages. Niche innovators such as Bioprocess Control AB, Bio-Process Group, and TOYOBO Co., Ltd. are strengthening the market by offering specialized solutions for process analytics and upstream optimization, supporting efficient scale-up for biotech firms and research institutions.

Strategic collaborations—such as those involving CMC Biologics, Patheon, and multinational pharmaceutical companies—underscore the growing importance of contract biomanufacturing. These partnerships help streamline the transition from small-scale R&D to commercial-scale production while maintaining regulatory and quality standards.

With global demand for biologics and advanced therapies rising sharply, the market increasingly favors companies capable of integrating automation, AI-driven process optimization, and sustainable manufacturing practices. Firms that combine flexibility, scalability, and innovation are positioned to lead future developments in bioprocessing.

Key Large and Small-scale Bioprocessing Companies

• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Danaher (Cytiva)
• Corning Inc.
• Sartorius AG
• Lonza
• CESCO BIOENGINEERING CO., LTD
• Bio-Process Group
• BPC Instruments AB
• Eppendorf AG
• Getinge AB
• PBS Biotech, Inc.
• Bio-Synthesis, Inc.
• Meissner Filtration Products, Inc.
• Entegris
• KUHNER AG
• Saint-Gobain
• ExcellGene SA
• Repligen Corporation
• Avantor, Inc.
• CerCell A/S
• Univercells Technologies
• Distek, Inc.
• F. Hoffmann-La Roche Ltd

Explore Horizon Databook - The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The large and small-scale bioprocessing market is undergoing rapid expansion due to rising global demand for biologics and advanced therapies. Increasing adoption of single-use technologies, modular manufacturing systems, and automated workflow solutions is enabling faster, more cost-efficient production. As companies continue to invest in scaling capacity and integrating digital tools, the industry is poised for strong long-term growth through 2033. Organizations that prioritize innovation, flexibility, and strategic collaboration will be best positioned to capitalize on the growing biologics and biomanufacturing ecosystem.